1. Scrip

Fruzaqla Adds Sparkle To Takeda’s First Half

Pen Helps Mainstay Entyvio

 
• By Ian Haydock

Continued growth for mainstay Entyvio and cancer newcomer Fruzaqla drove growth at Takeda in the fiscal first half, with the Japanese major brightening its outlook for the full year.

Takeda Tokyo HQ entrance
Japan now only 10% of Takeda's revenues but firm says it's committed to home market • Source: Takeda

Takeda’s 13.4% rise in reported revenue to JPY2,384.0bn ($15.63bn; +5.0% at constant currencies) in the fiscal first half was driven in large part by mainstay blockbuster Entyvio (vedolizumab).

But while the for ulcerative colitis and Crohn’s disease drug grew 10.7% to JPY473.2bn globally, and US growth (+13% at...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Scrip

More from Focus On Asia

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Citeline Japan Awards 2025 - Enter Now!

 
• By Ian Haydock and Lisa Takagi

The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get those submissions in by this date. Sponsorship opportunities and tables for the event are also available.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.